Diffuse exanthema in a patient receiving varenicline

American Journal of Health-System Pharmacy

Volumn 65, Issue 13, 2008, Pages 1239-1241

  Song, Wei ^a   Miller, William A ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Drugs, adverse reactions; Exanthema; Geriatrics; Nicotinic agonists; Varenicline

Indexed keywords

CARISOPRODOL; DIPHENHYDRAMINE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; LEVOTHYROXINE; OXYCODONE; PLACEBO; PREDNISONE; QUINAPRIL; SALBUTAMOL; SIMVASTATIN; TIOTROPIUM BROMIDE; VARENICLINE;

ABDOMINAL PAIN; AGED; ARTICLE; CASE REPORT; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; DERMATITIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DRY SKIN; DYSLIPIDEMIA; ECZEMA; ERYTHEMA; FEMALE; GERIATRIC PATIENT; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOTHYROIDISM; INSOMNIA; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; SMOKING CESSATION; SURGICAL PATIENT; TOBACCO DEPENDENCE; URTICARIA;

EID: 46049097989     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070458     Document Type: Article

References (13)

1. Lam S, Patel PN. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiol Rev. 2007; 15:154-61.
2. Gonzales D, Rennard SI, Nides M et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006; 296:47-55.
3. Jorenby DE, Hays JT, Rigotti NA et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006; 296:56-63. [Erratum, JAMA. 2006; 296:1355.]
4. Tonstad S, Tonnesen P, Hajek P et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006; 296:64-71.
5. Chantix (varenicline tartrate) package insert. New York: Pfizer Labs; 2007 May.
6. Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: implications for management. Am J Clin Dermatol. 2003; 4:407-28.
7. Shepherd GM. Hypersensitivity reactions to drugs: evaluation and management. Mt Sinai J Med. 2003; 70:113-25.
8. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev. 2001; 53:357-79.
9. Brönnimann M, Yawalkar N. Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy? Curr Opin Allergy Clin Immunol. 2005; 5:317-21.
10. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
11. Lee A, Thomson J. Drug-induced skin reactions. In: Lee A, ed. Adverse drug reactions. 2nd ed. London: Pharmaceutical Press; 2006:125-56.
12. Hukkanen J, Väisänen T, Lassila A et al. Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003; 304:745-52.
13. Lin JH, Chiba M, Baillie T. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev. 1999; 51:135-58.